Mylan’s Copaxone Suit Against Teva Should Survive, Judge Says

Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple sclerosis drug, a specially appointed judge recommended.

“The Mylan Complaint has alleged a set of facts from which to plausibly infer that the Rebate Agreements and Switch Agreements adversely affected competition; the facts alleged are sufficient to survive the motions to dismiss at this early stage of the case,” Special Master Faith S. Hochberg wrote in a Thursday report and recommendation for the US District Court for the District of ...